STOCK TITAN

REGENXBIO to Host Conference Call on March 1 to Discuss Fourth Quarter and Full-Year 2020 Financial Results and Recent Operational Highlights

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary

REGENXBIO Inc. (RGNX) announced a conference call scheduled for March 1, 2021, at 4:30 p.m. ET, to discuss its financial results for the fourth quarter and full year 2020, along with operational highlights. The call can be accessed via phone or through a webcast on the company's website. REGENXBIO is recognized for its innovative gene therapy solutions using its NAV Technology Platform, which includes a range of adeno-associated virus vectors aimed at therapeutic advancements across various medical fields.

Positive
  • None.
Negative
  • None.

ROCKVILLE, Md., Feb. 22, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Monday, March 1, 2021, at 4:30 p.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2020, and recent operational highlights.

To access the live call by phone, dial (855) 422-8964 (domestic) or (210) 229-8819 (international) and enter the passcode 6298809. To access a live or recorded webcast of the call, please visit the Investors section of the REGENXBIO website at www.regenxbio.com. The recorded webcast will be available for approximately 30 days following the call.

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

Contacts:

Tricia Truehart
Investor Relations and Corporate Communications
347-926-7709
ttruehart@regenxbio.com

Investors:
Brendan Burns, 212-600-1902
brendan@argotpartners.com

Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com

(PRNewsfoto/REGENXBIO Inc.)

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-march-1-to-discuss-fourth-quarter-and-full-year-2020-financial-results-and-recent-operational-highlights-301232648.html

SOURCE REGENXBIO Inc.

FAQ

When will REGENXBIO report its Q4 and full-year 2020 financial results?

REGENXBIO will report its Q4 and full-year 2020 financial results on March 1, 2021.

How can investors access the REGENXBIO conference call?

Investors can access the conference call by dialing (855) 422-8964 for domestic calls or (210) 229-8819 for international calls, entering passcode 6298809, or via a webcast on the REGENXBIO website.

What is the NAV Technology Platform used by REGENXBIO?

The NAV Technology Platform is REGENXBIO's proprietary adeno-associated virus gene delivery system, featuring exclusive rights to over 100 novel AAV vectors.

What time is the REGENXBIO conference call scheduled for?

The REGENXBIO conference call is scheduled for 4:30 p.m. ET on March 1, 2021.

REGENXBIO Inc.

NASDAQ:RGNX

RGNX Rankings

RGNX Latest News

RGNX Stock Data

510.79M
49.42M
7.39%
89.06%
10.09%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
ROCKVILLE